Searchable abstracts of presentations at key conferences in endocrinology

ea0056oc7.2 | Genomic and clinical aspects of endocrine tumours | ECE2018

Urine steroid metabolomics as a diagnostic tool for detection of adrenocortical malignancy – a prospective test validation study

Bancos Irina , Taylor Angela , Chortis Vasileios , Sitch Alice , Lang Katharina , Prete Alessandro , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beauschlein Felix , Ambroziak Urszula , Biehl Michael , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of abdominal imaging scans. Accuracy of currently available imaging tests to diagnose malignancy is poor. In a proof-of-concept study (JCE&M 2011;96(12):3775-84), we had demonstrated 90% sensitivity and specificity in detecting adrenocortical carcinoma (ACC) for urine steroid metabolomics, the combination of mass spectrometry-based steroid profiling and machine learning-based data analysis. This diagnostic performance is supe...

ea0056gp23 | Adrenal clinical | ECE2018

Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela , Doig Craig , Walsh Mark , Meimaridou Eirini , Jenkinson Carl , Rodriguez-Blanco Giovanny , Ronchi Cristina , Jaffri Alisha , Metherell Louise , Hebenstreit Daniel , Dunn Warwick , Arlt Wiebke , Foster Paul

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating human NNT mutations result in congenital adrenal insufficiency. We hypothesized NNT silencing in ACC cells will i...

ea0056p41 | Adrenal cortex (to include Cushing's) | ECE2018

Outcomes of patients undergoing surgery for primary aldosteronism based on adrenal venous sampling and/or radiological lateralisation indicate a role for both modalities in case selection

Davis Lauramay , Lewis Dylan , Clough Jennifer , Whitelaw Benjamin C , Gilbert Jackie , Diaz-Cano Salvador , Taylor David R , Vincent Royce P , Hubbard Jonathan , Galata Gabriele , Schulte Klaus-Martin , Aylwin Simon J B

Background: Adrenal venous sampling (AVS) is considered the gold standard for lateralisation of aldosterone production in patients with primary aldosteronism (PA). However, in some patients AVS is not technically successful and management may depend on radiological findings.Aim: To determine 1) the success rate of AVS and 2) the outcomes after surgery related to the lateralisation modality.Method: 156 patients were included who pre...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0065ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2019

Urine steroid metabolome analysis allows for metabolic risk stratification in 1309 prospectively recruited patients with benign adrenal tumours and different degrees of cortisol excess

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urszula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe Astrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , O'Reilly Michael W , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Benign adrenal tumours (AT) can be non-functioning (NFAT) or associated with cortisol excess, as indicated by failure to suppress serum morning cortisol to <50 nmol/l in the 1mg-dexamethasone suppression test (1 mg-DST). The latter group divides into patients with clinically overt signs of cortisol excess (adrenal Cushing’s syndrome, CUSH) and patients lacking CUSH signs (mild autonomous cortisol excess, MACE). Smaller series and a recent meta-analysis rep...

ea0065op6.4 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Chortis Vasileios , Nijman Thomas , Bancos Irina , Gilligan Lorna C , Taylor Angela E , Ronchi Cristina L , O'Reilly Michael W , Schreiner Jochen , Asia Miriam , Riester Anna , Terzolo Massimo , Libe Rosella , Quinkler Marcus , Canu Letizia , Paiva Isabel , Bugalho Maria J , Kastelan Darko , Dennedy M Conall , Sherlock Mark , Ambroziak Urszula , Vassiliadi Dimitra , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Objective: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) resection of ACC.Methods: 135 ACC patients from 14 clinical centres provided pos...

ea0067o21 | Oral Presentations | EYES2019

Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Chortis Vasileios , Bancos Irina , Nijman Thomas , Gilligan Lorna C , Taylor Angela E , Ronchi Cristina L , O'Reilly Michael W , Schreiner Jochen , Asia Miriam , Riester Anna , Terzolo Massimo , Libe Rosella , Quinkler Marcus , Canu Letizia , Paiva Isabel , Bugalho Maria J , Kastelan Darko , Dennedy M Conall , Sherlock Mark , Ambroziak Urszula , Vassiliadi Dimitra , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Objective: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) resection of ACC.Methods: 135 patients from 14 clinical centers provided post-op...

ea0063oc10.1 | Adrenal 2 | ECE2019

Steroid metabolomics: a rapid computational approach for accurate differentiation of inborn disorders of steroidogenesis

Baranowski Elizabeth S , Ghosh Sreejita , Shackleton Cedric HL , Taylor Angela E , Hughes Beverly A , Gilligan Lorna C , Utari Agustini , Faradz Sultana MH , van Herwaarden Antonius E , Claahsen-van der Grinten Hedi L , Biehl Michael , Guran Tulay , Bunte Kerstin , Tino Peter , Arlt Wiebke

Background: Measurement of steroid metabolite excretion in urine by gas chromatography-mass spectrometry (GC-MS) provides a comprehensive profile of an individual’s adrenal and gonadal steroid production. It has long been acknowledged as a useful tool for diagnosis of inborn disorders of steroidogenesis leading to congenital adrenal hyperplasia and disorders of sex development. Ratios of steroid metabolites can be employed as surrogates for enzymatic activities of distinc...

ea0041oc1.4 | Adrenal - Basic &amp; Clinical | ECE2016

Urine steroid metabolomics is a highly sensitive tool for post-operative recurrence detection in adrenocortical carcinoma

Chortis Vasileios , Bancos Irina , Sitch Alice J , Taylor Angela E , O'Neil Donna , Lang Katharina , Quinkler Marcus , Terzolo Massimo , Mannelli Massimo , Vassiliadi Dimitra , Ambroziak Urszula , Dennedy M. Conall , Sherlock Mark , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Context: Adrenocortical carcinoma (ACC) is an aggressive malignancy with high recurrence rates. Regular post-operative follow-up imaging is essential, but associated with high radiation exposure and frequent diagnostic ambiguity. Urine steroid metabolomics has been described as a novel diagnostic tool for the detection of adrenocortical malignancy. Here we present the first clinical study assessing the performance of this innovative approach in the follow-up of patients with c...